This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow An erratum has been published
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowReprints and Permissions
Right arrow Copyright Information
Right arrow Books from ASM Press
Right arrow MicrobeWorld
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Genovesi, E. V.
Right arrow Articles by Clark, J. M.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Genovesi, E. V.
Right arrow Articles by Clark, J. M.

 Previous Article  |  Next Article 

Antimicrobial Agents and Chemotherapy, December 1998, p. 3209-3217, Vol. 42, No. 12
0066-4804/98/$04.00+0
Copyright © 1998, American Society for Microbiology. All rights reserved.

Efficacy of the Carbocyclic 2'-Deoxyguanosine Nucleoside BMS-200475 in the Woodchuck Model of Hepatitis B Virus Infection

E. V. Genovesi,* L. Lamb, I. Medina, D. Taylor, M. Seifer,dagger S. Innaimo, R. J. Colonno, D. N. Standring,dagger and J. M. Clark

Pharmaceutical Research Institute, Bristol-Myers Squibb, Wallingford, Connecticut 06492

Received 8 May 1998/Returned for modification 1 July 1998/Accepted 11 September 1998

Daily oral treatment with the cyclopentyl 2'-deoxyguanosine nucleoside BMS-200475 at doses ranging from 0.02 to 0.5 mg/kg of body weight for 1 to 3 months effectively reduced the level of woodchuck hepatitis virus (WHV) viremia in chronically infected woodchucks as measured by reductions in serum WHV DNA levels and endogenous hepadnaviral polymerase activity. Within 4 weeks of daily therapy with 0.5 or 0.1 mg of BMS-200475 per kg, endogenous viral polymerase levels in serum were reduced about 1,000-fold compared to pretreatment levels. Serum WHV DNA levels determined by a dot blot hybridization technique were comparably decreased in these treated animals. In the 3-month study, the sera of animals that had undetectable levels of WHV DNA by the dot blot technique were further analyzed by a highly sensitive semiquantitative PCR assay. The results indicate that BMS-200475 therapy reduced mean WHV titers by 107- to 108-fold, down to levels as low as 102 to 103 virions/ml of serum. Southern blot hybridization analysis of liver biopsy samples taken from animals during and after BMS-200475 treatment showed remarkable reductions in the levels of WHV DNA replicative intermediates and in the levels of covalently closed circular viral DNA. WHV viremia in BMS-200475-treated WHV carriers eventually returned to pretreatment levels after therapy was stopped. These results indicate that BMS-200475 should be evaluated in clinical trials for the therapy of chronic human hepatitis B virus infections.

* Corresponding author. Mailing address: Bristol-Myers Squibb Pharmaceutical Research Institute, 5 Research Parkway, Wallingford, CT 06492-7660. Phone: (203) 677-6570. Fax: (203) 677-6771. E-mail: eugene_v_genovesi{at}ccmail.bms.com.

dagger Present address: Schering Plough Pharmaceutical Research Institute, Kenilworth, N.J. 07033.

Antimicrobial Agents and Chemotherapy, December 1998, p. 3209-3217, Vol. 42, No. 12
0066-4804/98/$04.00+0
Copyright © 1998, American Society for Microbiology. All rights reserved.


This article has been cited by other articles:

  • Michalak, T. I., Zhang, H., Churchill, N. D., Larsson, T., Johansson, N.-G., Oberg, B. (2009). Profound Antiviral Effect of Oral Administration of MIV-210 on Chronic Hepadnaviral Infection in a Woodchuck Model of Hepatitis B. Antimicrob. Agents Chemother. 53: 3803-3814 [Abstract] [Full Text]  
  • Scarsi, K. K., Darin, K. M. (2009). Chronic Hepatitis B Infection: Principles of Therapy. Journal of Pharmacy Practice 22: 359-387 [Abstract]  
  • Mason, W. S., Xu, C., Low, H. C., Saputelli, J., Aldrich, C. E., Scougall, C., Grosse, A., Colonno, R., Litwin, S., Jilbert, A. R. (2009). The Amount of Hepatocyte Turnover That Occurred during Resolution of Transient Hepadnavirus Infections Was Lower When Virus Replication Was Inhibited with Entecavir. J. Virol. 83: 1778-1789 [Abstract] [Full Text]  
  • Zimmerman, K. A., Fischer, K. P., Joyce, M. A., Tyrrell, D. L. J. (2008). Zinc Finger Proteins Designed To Specifically Target Duck Hepatitis B Virus Covalently Closed Circular DNA Inhibit Viral Transcription in Tissue Culture. J. Virol. 82: 8013-8021 [Abstract] [Full Text]  
  • Lu, M., Yao, X., Xu, Y., Lorenz, H., Dahmen, U., Chi, H., Dirsch, O., Kemper, T., He, L., Glebe, D., Gerlich, W. H., Wen, Y., Roggendorf, M. (2008). Combination of an Antiviral Drug and Immunomodulation against Hepadnaviral Infection in the Woodchuck Model. J. Virol. 82: 2598-2603 [Abstract] [Full Text]  
  • Menne, S., Asif, G., Narayanasamy, J., Butler, S. D., George, A. L., Hurwitz, S. J., Schinazi, R. F., Chu, C. K., Cote, P. J., Gerin, J. L., Tennant, B. C. (2007). Antiviral Effect of Orally Administered ( )-{beta}-D-2-Aminopurine Dioxolane in Woodchucks with Chronic Woodchuck Hepatitis Virus Infection. Antimicrob. Agents Chemother. 51: 3177-3184 [Abstract] [Full Text]  
  • Gao, W., Hu, J. (2007). Formation of Hepatitis B Virus Covalently Closed Circular DNA: Removal of Genome-Linked Protein. J. Virol. 81: 6164-6174 [Abstract] [Full Text]  
  • Foster, W. K., Miller, D. S., Scougall, C. A., Kotlarski, I., Colonno, R. J., Jilbert, A. R. (2005). Effect of Antiviral Treatment with Entecavir on Age- and Dose-Related Outcomes of Duck Hepatitis B Virus Infection. J. Virol. 79: 5819-5832 [Abstract] [Full Text]  
  • Summers, J., Jilbert, A. R., Yang, W., Aldrich, C. E., Saputelli, J., Litwin, S., Toll, E., Mason, W. S. (2003). Inaugural Article: Hepatocyte turnover during resolution of a transient hepadnaviral infection. Proc. Natl. Acad. Sci. USA 100: 11652-11659 [Abstract] [Full Text]  
  • Foster, W. K., Miller, D. S., Marion, P. L., Colonno, R. J., Kotlarski, I., Jilbert, A. R. (2003). Entecavir Therapy Combined with DNA Vaccination for Persistent Duck Hepatitis B Virus Infection. Antimicrob. Agents Chemother. 47: 2624-2635 [Abstract] [Full Text]  
  • Karayiannis, P. (2003). Hepatitis B virus: old, new and future approaches to antiviral treatment. J Antimicrob Chemother 51: 761-785 [Abstract] [Full Text]  
  • Levine, S., Hernandez, D., Yamanaka, G., Zhang, S., Rose, R., Weinheimer, S., Colonno, R. J. (2002). Efficacies of Entecavir against Lamivudine-Resistant Hepatitis B Virus Replication and Recombinant Polymerases In Vitro. Antimicrob. Agents Chemother. 46: 2525-2532 [Abstract] [Full Text]  
  • Yamamoto, T., Litwin, S., Zhou, T., Zhu, Y., Condreay, L., Furman, P., Mason, W. S. (2002). Mutations of the Woodchuck Hepatitis Virus Polymerase Gene That Confer Resistance to Lamivudine and 2'-Fluoro-5-Methyl-{beta}-L-Arabinofuranosyluracil. J. Virol. 76: 1213-1223 [Abstract] [Full Text]  
  • Marion, P. L., Salazar, F. H., Winters, M. A., Colonno, R. J. (2002). Potent Efficacy of Entecavir (BMS-200475) in a Duck Model of Hepatitis B Virus Replication. Antimicrob. Agents Chemother. 46: 82-88 [Abstract] [Full Text]  
  • Le Guerhier, F., Pichoud, C., Jamard, C., Guerret, S., Chevallier, M., Peyrol, S., Hantz, O., King, I., Trépo, C., Cheng, Y.-C., Zoulim, F. (2001). Antiviral Activity of {beta}-L-2',3'-Dideoxy-2',3'-Didehydro-5-Fluorocytidine in Woodchucks Chronically Infected with Woodchuck Hepatitis Virus. Antimicrob. Agents Chemother. 45: 1065-1077 [Abstract] [Full Text]  
  • Bryant, M. L., Bridges, E. G., Placidi, L., Faraj, A., Loi, A.-G., Pierra, C., Dukhan, D., Gosselin, G., Imbach, J.-L., Hernandez, B., Juodawlkis, A., Tennant, B., Korba, B., Cote, P., Marion, P., Cretton-Scott, E., Schinazi, R. F., Sommadossi, J.-P. (2001). Antiviral L-Nucleosides Specific for Hepatitis B Virus Infection. Antimicrob. Agents Chemother. 45: 229-235 [Abstract] [Full Text]  
  • Zhu, Y., Yamamoto, T., Cullen, J., Saputelli, J., Aldrich, C. E., Miller, D. S., Litwin, S., Furman, P. A., Jilbert, A. R., Mason, W. S. (2001). Kinetics of Hepadnavirus Loss from the Liver during Inhibition of Viral DNA Synthesis. J. Virol. 75: 311-322 [Abstract] [Full Text]  
  • Hostetler, K. Y., Beadle, J. R., Hornbuckle, W. E., Bellezza, C. A., Tochkov, I. A., Cote, P. J., Gerin, J. L., Korba, B. E., Tennant, B. C. (2000). Antiviral Activities of Oral 1-O-Hexadecylpropanediol-3-Phosphoacyclovir and Acyclovir in Woodchucks with Chronic Woodchuck Hepatitis Virus Infection. Antimicrob. Agents Chemother. 44: 1964-1969 [Abstract] [Full Text]  
  • Zhang, Y.-Y., Summers, J. (2000). Low Dynamic State of Viral Competition in a Chronic Avian Hepadnavirus Infection. J. Virol. 74: 5257-5265 [Abstract] [Full Text]  
  • Le Guerhier, F., Pichoud, C., Guerret, S., Chevallier, M., Jamard, C., Hantz, O., Li, X.-Y., Chen, S.-H., King, I., Trépo, C., Cheng, Y.-C., Zoulim, F. (2000). Characterization of the Antiviral Effect of 2',3'-Dideoxy-2', 3'-Didehydro-beta -L-5-Fluorocytidine in the Duck Hepatitis B Virus Infection Model. Antimicrob. Agents Chemother. 44: 111-122 [Abstract] [Full Text]  
  • Zhou, T., Saputelli, J., Aldrich, C. E., Deslauriers, M., Condreay, L. D., Mason, W. S. (1999). Emergence of Drug-Resistant Populations of Woodchuck Hepatitis Virus in Woodchucks Treated with the Antiviral Nucleoside Lamivudine. Antimicrob. Agents Chemother. 43: 1947-1954 [Abstract] [Full Text]  
  • Seifer, M., Hamatake, R. K., Colonno, R. J., Standring, D. N. (1998). In Vitro Inhibition of Hepadnavirus Polymerases by the Triphosphates of BMS-200475 and Lobucavir. Antimicrob. Agents Chemother. 42: 3200-3208 [Abstract] [Full Text]  


Copyright © 2009 by the American Society for Microbiology.   For an alternate route to Journals.ASM.org, visit: http://intl-journals.asm.org | More Info»